# Shanghai Waker Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-waker-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.wakerbio.com
- Total disclosed funding: $14M
- Latest round: Series A (Nov 27, 2025)
- Investors on record: 3

## About

Based in Shanghai, China and founded in 2021, Shanghai Weike Biotechnology Co., Ltd., dba Waker Bioscience or Shanghai Waker Biotechnology, develops genomic-safety evaluation technologies and analytical tools for the gene-therapy industry. Its LTA-PCR and TES systems form the world’s first validated ISA detection method and have supported multiple FDA and EMA-approved gene-therapy mutation-risk assessments. The company works with gene-therapy developers, biotech firms, and pharmaceutical R&D teams to deliver insertion-mutation risk evaluations, high-accuracy CRISPR/Cas9 off-target profiling, and optimized sgRNA selection services. It offers proprietary genomic-analysis platforms, ISA detection assays, and expert technical support to help customers improve the safety and precision of gene-therapy programs. The company generates revenue through genomic-analysis service fees, specialized assay offerings, and enterprise partnerships for customized gene-therapy safety evaluations.
In November 2025, Shanghai Waker Biotechnology closed CNY 100 million in Series A funding led by new investor Shenzhen Capital Real Estate Fund, with participation from new investor Jinkong Qiyuan Capital.

## Funding rounds

- Series A, Nov 27, 2025, $14M — Shenzhen Capital Real Estate Fund, Jinkong Qiyuan Capital
- Angel, Sep 1, 2022 — BGI Co-WIN Investment Management

## Investors

- BGI Co-WIN Investment Management (https://capitalatlas.ai/funds/bgi-co-win-investment-management) — Angel
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series A